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Abstract: Three to four months after hospitalisation for COVID-19 pneumonia, the most frequently
described alteration in respiratory function tests (RFTs) is decreased carbon monoxide transfer
capacity (DLCO). Methods: This is a prospective cohort study that included patients hospitalised
because of SARS-CoV-2 pneumonia, three months after their discharge. A clinical evaluation,
analytical parameters, chest X-ray, six-minute walk test, spirometry and DLCO–DLNO analysis were
performed. Demographic variables, comorbidities, and variables related to the severity of the
admission were recorded. Results: Two hundred patients completed the study; 59.5% men, age 62
years, 15.5% admitted to the intensive care unit. The most frequent functional alteration, in 27% of
patients, was in the DLCO–DLNO combination. This alteration was associated with age, male sex,
degree of dyspnoea, poorer perception of health, and limited ability for physical effort. These patients
also presented higher levels of D-Dimer and more residual radiological alterations. In 42% of the
patients with diffusion alterations, only reduced DLNO was presented, along with lower D-Dimer
levels and less capillary volume involvement. The severity of the process was associated with the
reduction in DLCO–DLNO. Conclusions: The most sensitive RFT for the detection of the sequelae of
COVID-19 pneumonia was the combined measurement of DLCO–DLNO and this factor was related
to patient health status and their capacity for physical exertion. In 40% of these cases, there was only
a reduction in DLNO, a finding that may indicate less pulmonary vascular involvement.
Keywords: COVID-19; pneumonia; sequelae; respiratory function tests; diffusion capacity; DLCO;
DLNO
1. Introduction
To date, only a limited number of studies have been published that analysed the
clinical and functional alterations of patients hospitalised for SARS-COV-2 pneumonia,
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3–4 months after their hospital discharge [1–10]. In these cases of severe COVID-19 pneu-
monia, the most frequently described alterations are a decrease in forced vital capacity
(FVC), carbon monoxide transfer capacity (DLCO), total lung capacity, and reduction in
the 6-min walk test (6MWT) [1–10]. However, the results described in these studies are
not homogeneous. Although the most frequently described alteration was a decrease in
DLCO, the reported number of patients affected by this pathology varies between 15% and
80%. Moreover, some studies define DLCO according to the percentage of a reference value,
while others define it in reference to the lower limit of normality (LLN) [1–10].
Publication of the first studies analysing functional alterations in patients in the first
four weeks after discharge from hospitalisation with COVID-19 pneumonia [11] generated
an interesting scientific debate about which value of DLCO that might be used to detect
functional alterations, as well as the need to adjust these values according to the alveolar
volume (VA). However, more studies will be required to clarify the value of these determi-
nations in the detection of the pulmonary sequelae of this virus [12,13]. Because patients
with severe pulmonary involvement or interstitial involvement secondary to COVID-19
may present small vessel endothelial damage and altered pulmonary hemodynamic [14,15],
some authors suggested that the combined determination of DLCO along with the diffusion
capacity of nitric oxide (DLNO) could help detect these vascular and interstitial changes in
patients recovering after hospitalisation for these processes [16,17], as already described
for other pulmonary conditions [18–20].
The combined determination of DLCO and DLNO is advantageous over finding the
DLCO alone because, in addition to providing more information, DLNO testing is more
stable over time and requires fewer adjustments [17,18,21]. Nonetheless, the usefulness of
measuring DLNO in determining the sequelae of severe COVID-19 pneumonia has only
been analyzed in one study [17]. The available evidence regarding the relationship between
DLCO alterations and the clinical situation of the patients (e.g., dyspnoea, limitations upon
physical effort or in terms of quality of life), or with other analytical parameters, imaging,
or in other respiratory function tests (RFTs), is also very heterogenous.
Therefore, we carried out this present study with the aim of identifying alterations
in respiratory function in patients three months after their discharge from hospital for
COVID-19 pneumonia. We determined, among other tests and functional alterations, the
combined DLCO and DLNO levels in order to determine whether these potential alterations
were related to the clinical situation of these patients and if they could be used to predict
patient evolution based on their demographics or on the characteristics of the pneumonic
process itself.
2. Materials and Methods
We included consecutive patients aged 18 and 90 years who had been discharged from
a tertiary hospital between March and May 2020, after admission for COVID-19 pneumonia
(confirmed by a positive PCR result for SARS-CoV-2 in the nasopharyngeal exudate or
bronchoalveolar lavage). We excluded any patients who received institutional care (e.g.,
residences for the elderly or severely disabled), as well as any individuals who refused
or were unable to sign the informed consent document. The study was approved by the
Galicia Clinical Research Ethics Committee (registration number 245/2020) in April 2020.
All patients attended a face-to-face consultation 12 ± 1 weeks after their hospital
discharge, during which we performed all the planned clinical evaluations, a chest X-ray in
two projections, blood tests, and a lung function study. In addition to the sociodemographic
variables (age, sex, height, and weight), we also recorded the patients’ history of smoking,
significant comorbidities (Table 1), their general health status before admission according
to the ECOG (Eastern Cooperative Oncology Group) scale, and variables at the time of
admission including arterial oxygen saturation and analytical parameters (minimum peak
of total lymphocytes and maximum lactate dehydrogenase (LDH), C-reactive protein (CRP),
and D-Dimer), Pneumonia Severity Index (PSI) prognosis score, unilateral or bilateral lung
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involvement, as well as their subsequent evolution such as intensive care unit (ICU)
admission, non-invasive ventilatory support, and the total number of days of admission.
Table 1. Sociodemographic, clinical, and general characteristics of the pneumonic process caused by
COVID-19 in the patients included in the study.
Variables TotalN = 200
Demographics and Clinics before Admission
Male sex, N (%), 119 (59.5)
Age, years 62 (50–71)
Body mass index (Kg/m2) 28.7 (25.9–31.9)
Previous and current smoker, N (%) 84 (42)
History of chronic cardiopathy, N (%) * 37 (18.5)
History of diabetes, N (%) 23 (11.5)
History of hypertension, N (%) 74 (37)
History of COPD, N (%) 6 (3)
History of chronic renal failure, N (%) 7 (3.5)
ECOG score 1 (1–2)
ECOG score ≥ 2, N (%) 51 (25.5)
In Relation to the Pneumonic Process
Bilateral radiographic involvement, N (%) 139 (69.5)
Oxygen saturation at hospital admission 96 (94–98)
Pneumonia Severity Index 61 (49–75)
Pneumonia Severity Index ≥ 3, N (%) 62 (31)
Need non-invasive ventilatory support, N (%) 12 (6)
ICU admission, N (%) 31 (15.5)
Lowest level of lymphocites (109/L) 0.75 (0.55–1.04)
Maximum level of C-reactive protein (mg/L) 83.3 (31–160.1)
Maximum level of LDH (U/L) 295 (227.7–386.7)
Maximum level of D-dimer (ng/mL) ** 1150.1 (476.2–2856)
Length of stay (days) 7 (4–13)
* History of ischaemic heart disease or chronic heart failure; ** Available in 94 patients only; COPD: Chronic
obstructive pulmonary disease; ECOG: Eastern Cooperative Oncology Group; ICU: Intensive care unit.
2.1. Clinical, Health, Radiographic, and Analytical Evaluation at 12 Weeks
The level of dyspnoea was determined according to the modified Medical Research
Council (mMRC) scale. The patient health status was evaluated by applying the Spanish
version of the Nottingham Health Profile (NHP) [22]. All the patients underwent a chest
X-ray in two different projections; these results were reported by consensus by two expert
radiologists blinded to the clinical history, who compared them with the studies from the
time of discharge and from six months prior to hospital admission (if available); these
results were reported either as the complete resolution of the lesions (normal study or
similar to the one existing prior to admission) or as incomplete resolution. The values
for total lymphocytes, LDH, CRP, D-Dimer, and the N-terminal portion of pro-natriuretic
peptide type B (NT-proBNP) were determined from the blood samples.
2.2. Respiratory Function Tests at 12 Weeks
The RFTs were conducted with MasterScreen PFT equipment (Viasys, CareFusion,
Würzburg, Germany) with SentrySuiteTM software and included a forced spirometry and
bronchodilator test, following the recommendations of the American Thoracic Society and
European Respiratory Society (ATS/ERS) [23] and using the values provided by the Global
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Lung Function Initiative (GLI) [24] equations as reference values. DLNO and DLCO were
measured simultaneously during a single breath maneuver using the above-mentioned
equipment, according to ERS recommendations [21]. After maximal expiration, the patients
were requested to inhale quickly and deeply in less than four seconds a gas mixture of 0.3%
CO, 9.0% He, 21% O2 and 400 ppm NO in N2 and inhaled from a plastic bag containing a
final concentration of NO of 50 ppm obtained ≤2 min before its use. The pressure curve
displayed during the occlusion showed whether the patient has held his/her breath and
the maneuver was accepted when pressure was <3 kPa. A breath-hold of 6 s was then
requested, followed by a rapid expiration. The first 0.75 L of expired gas was rejected and
the following 0.75 L was sampled in a bag, which was automatically analysed for NO, CO
and He. This washout volume was 0.5 L for subjects with a vital capacity <2 L. The actual
breath-hold time was calculated using the Jones and Meade method [25]. The linearity of
the electrochemical cell was checked by factory and the apparatus was calibrated for gas
fractions using automated procedures. The procedure was repeated after a 4-min wait, and
it was accepted if two successive DLNO and DLCO measurements were within 17 and
3 mL/min/mmHg, respectively. If this was not the case, additional measurements (up
to five in total) were performed. The mean of two chosen manoeuvres was used for the
subsequent analyses.
The inert gas, He, was used in the calculation of alveolar volume (VA) by means of the
He-dilution technique. The values of the membrane component of diffusing capacity for
CO (DMCO) and of the pulmonary capillary blood volume (Vc) were calculated ac-cording
to the model by Guénard et al. [26]. All diffusing capacity values were corrected for the
haemoglobin levels obtained on the same day of the study and interpreted ac-cording to
the reference equations proposed by Zavorsky et al. [21].
The 6MWT was performed in duplicate, along a 30 m corridor, following the ATS
recommendations [27]. The oxygen saturation and scores on the Borg dyspnoea scale were
recorded before starting and at the end of the 6MWT, and the differences and total distance
walked were calculated.
2.3. Statistical Analysis
The quantitative variables were expressed as the median and 25% and 75% percentiles.
Qualitative variables were expressed by their number and percentage, except for the
percentage of RFT alterations, for which we calculated the 95% confidence interval (95%
CI). Numerical variables were compared using the Mann–Whitney U test and qualitative
variables were compared using Chi-squared or Fisher exact tests. Comparison of the
frequencies of the different functional alterations was carried out using the McNemar test
and the degree of agreement was compared using Cohen’s kappa coefficient.
A comparative analysis of the demographic and clinical variables prior to admission
and was carried out. We also compared the severity of the pneumonic process among
patients with RFT alterations to the variables most frequently affected and to the clinical
situation variables (dyspnoea, physical exertion capacity, impact of exertion, and global
health status) at 12 weeks. To evaluate possible relationships independently of the vari-
ables related to DLNO alteration in the univariate analysis, a conditional forward logistic
regression model was constructed, which included all the variables that had obtained a
p < 0.05 in the univariate analysis, calculating the odds ratios (ORs) and their 95% CIs. SPSS
software for Windows (version 25; IBM Corp, Armonk, NY, USA) was used in all analyses.
3. Results
We consecutively evaluated 225 patients; 129 (57.3%) were male and the mean age
was 62 (50–71) years. Of the total cohort, 207 performed a valid and reproducible forced
spirometry, while 198 completed the bronchodilator test, and 200 completed the DLNO–
DLCO manoeuvres and 6MWT. The main characteristics of the patients who met the
inclusion criteria are summarised in Table 1.
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Table 2 describes the RFTs results. The most frequent alteration in RFTs was a reduction
in DLCO (<LLN), which was observed in 58 (29%) of the patients and was significantly
higher than all the other tests performed (p < 0.001); 24 patients (12%) had a DLNO < LLN
but with a DLCO > LLN, and both these figures were altered in 34 (17%) of them. All
patients with DLCO < LLN also presented DLNO < LLN. The concordance between the
alterations in the different spirometry and diffusion variables is shown in Table 3; the only
high values were between DLNO and DLCO, DLNO and DMCO, and KNO and KCO.
Table 2. Results of respiratory function tests at 12 weeks.
Spirometry Values and Frequencies
FVC, L 3.62 (3.02–4.32)
FVC, % of predicted 103 (92.5–114.7)
FVC < LLN, N (% (IC 95%)) 9 (4.3 (1.5–7.1))
FEV1, L 2.9 (2.43–3.45)
FEV1, of predicted 104 (95.2–114)
FEV1 < LLN, N (% (IC 95%)) 9 (4.3 (1.5–7.1))
FEV1/FVC (%) 79 (75–84)
FEV1/FVC < LLN, N (% (IC 95%)) 9 (4.3 (1.5–7.1))
Post-broncodilation Changes Values and Frequencies
FVC, L 0.680 (0.52–0.720)
FVC, % 1 (−2–5)
FEV1, L 0.120 (0.55–0.210)
FEV1, % 4 (2–8)
Positive bronchodilator test, N (% (IC 95%)) 13 (6.5 (3–10.1))
Gas Diffusion Values and Frequencies
DLCO, mL/min/mmHg 21.2 (16.4–25.7)
DLCO, % of predicted 84 (74–97)
DLCO < LLN, N (% (IC 95%)) 34 (17 (11.7–22.1))
KCO, mL/min/mmHg/L 4.3 (3.7–4.8)
KCO, % of predicted 96 (84–105)
KCO < LLN, N (% (IC 95%)) 13 (6.5 (3.1–9.9))
DLNO, mL/min/mmHg 99.1 (73.1–115.5)
DLNO, % of predicted 76.5 (68.2–87.0)
DLNO < LLN, N (% (IC 95%)) 58 (29 (22.7–35.3))
KNO, mL/min/mmHg/L 19.3 (16.6–21.6)
KNO, % of predicted 89.7 (83–99)
KNO < LLN, N (% (IC 95%)) 29 (10.5 (6.2–14.8))
DMCO, mL/min/mmHg 81.5 (59–99.7)
DMCO, % of predicted 69 (57–80)
DMCO < LLN, N (% (IC 95%)) 58 (29 (22.7–35.3))
VC, mL 54.3 (44–65)
VC, % of predicted 85 (74–97.7)
VC < LLN (N, % (IC 95%)) 20 (10 (5.8–14.2))
VA, L 4.9 (4.2–5.7)
VA, % of predicted 87 (77.2–94)
VA < LLN, N (% (IC 95%)) 41 (20.5 (14.9–26.1))
DLCO: diffusion capacity of carbon monoxide; DLNO: diffusion capacity of nitric oxide; DMNO: membrane
conductance of nitric oxide; KCO: Rate of uptake of carbon monoxide from alveolar gas; KNO: Rate of uptake of
nitric oxide from alveolar gas; FEV1: forced expiratory volume in first one second; FVC: forced vital capacity;
LLN: lower limits of normal; VA: alveolar lung volume; VC: pulmonary capillary blood volume.
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Table 3. Concordance between the alteration between the different functional tests performed, including the coincident


















N = 58 34 (0.67) 12 (0.26) 17 (0.32) 31 (0.51) 47 (0.73) 17 (0.34) 6 (0.53) 8 (0.56)
DLCO < LLN
N = 34 11 (0.41) 14 (0.43) 22 (0.49) 30 (0.55) 16 (0.53) 4 (0.15) 5 (0.18)
KCO < LLN
N = 13 13 (0.74) 9 (0.26) 10 (0.19) 9 (0.51) 2 (0.16) 3 (0.25)
KNO < LLN
N = 29 10 (0.21) 15 (0.27) 11 (0.49) 2 (0.09) 4 (0.23)
VA < LLN
N = 8 32 (0.53) 13 (0.28) 7 (0.25) 7 (0.23)
DMCO < LLN
N = 58 12 (0.19) 5 (0.10) 6 (0.12)
VC < LLN
N = 20 4 (0.26) 5 (0.32)
FVC < LLN
N = 9 4 (0.51)
DLCO: diffusion capacity of carbon monoxide; DLNO: diffusion capacity of nitric oxide; DMNO: membrane conductance of nitric oxide;
KCO: Rate of uptake of carbon monoxide from alveolar gas; KNO: Rate of uptake of nitric oxide from alveolar gas; FEV1: forced expiratory
volume in first one second; FVC: forced vital capacity; LLN: lower limits of normal; VA: alveolar lung volume; VC: pulmonary capillary
blood volume.
Table 4 shows the results for the patient clinical situation, health status, and capacity
for physical exertion (as determined using the 6MWT) 12 weeks after discharge, both for
the entire sample and dichotomised according to whether the patient DLNO was lower or
higher than the LLN. Patients with a reduced DLNO presented a higher level of dyspnoea,
and a greater number of altered health status dimensions (especially at the expense of
physical mobility and social isolation), and a lower capacity for physical exertion, which
more strongly impacted their oxygen saturation. They also had higher D-Dimer values
and the lesions on their chest radiographs persisted for longer. Furthermore, 34 of the
58 patients who had a reduced DLNO also showed a decreased DLCO.
Table 5 compares these same variables depending on whether the functional alteration
was detected only DLNO, or in both DLCO and DLNO. Proportionally more patients with
an altered DLNO but not an altered DLCO were younger females. The presence or absence
of a reduction in DLCO in patients with decreased DLNO did not discriminate between
individuals with different levels of dyspnoea, health status, tolerance to physical exertion,
radiological resolution, or laboratory disorders, except for D-dimer levels, which were
higher in patients with decreased DLCO and reduced DLNO. The Vc < LLN in 1/24 (4.2%)
patients with a reduced DLNO but normal DLCO versus 16/34 (47.1%) with a DLNO and
reduced DLCO (p = 0.0004).
Among the patients with a DLNO < LLN, those with an altered DLNO but DLCO > LLN
presented significant differences (p < 0.05) in terms of mobility, the social dimensions of the
NHP, and both in the drop in oxygen saturation during the 6MWT and the final oxygen
saturation afterwards (Table 5).
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Table 4. Degree of dyspnoea, health status, capacity for physical exertion, analytical determinations, and radiological
resolution at 12 weeks, according to whether DLNO < LLN or not.




N = 58 p
Dyspnoea According to mMRC
Dyspnoea ≥ 1, N (%) 89 (44) 55 (38.7) 34 (58.6) 0.01
Dyspnoea ≥ 2, N (%) 24 (12) 12 (8.4) 12 (20.6) 0.01
Dyspnoea 0.0 (0–1) 0 (0–1) 1 (0–1) 0.001
Health Status According to
Nottingham Health Profile
Energy 0 (0–33.3) 0 (0–33.3) 0 (0–33.3) 0.12
Pain 12.5 (0–37.5) 12.5 (0–37.5) 12.5 (0–62.5) 0.15
Physical mobility 12.5 (0–37.5) 12.5 (0–37.7) 25 (0–50) 0.02
Emotional reactions 11.1 (0–33.3) 11.1 (0–22.2) 11.1 (0–36.1) 0.21
Sleep 20 (0–60) 20 (0–60) 20 (0–80) 0.61
Social isolation 0 (0–0) 0 (0–0) 0 (0–20) 0.02
Number of limited areas 3 (2–4) 3 (1–4) 3.5 (2–5) 0.04
Exercise Capacity (6MWT)
6-min walking distance, m 457 (379.5–520.1) 473 (416–532) 411 (369.2–474) 0.04
Initial oxygen saturation, % 98 (97–99) 98 (97–99) 98 (97–98) 0.02
Final oxygen saturation, % 97 (95–98) 97 (96–98) 96 (94–97) 0.001
Oxygen saturation drop, % 1 (1–3) 1 (0–2) 2 (1–4) 0.001
Borg Scale Dyspnoea Start (1–10) 0 (0–1) 0 (0–1) 0 (0–1) 0.17
Final Borg scale dyspnoea (1–10) 2 (0–4) 2 (0–4) 1 (0–4) 0.75
Laboratory Parameters
Lymphocytes x109/L 1.8 (1.4–2.2) 1.7 (1.4–2.2) 1.8 (1.4–2.3) 0.43
C-reactive protein, mg/L 1.2 (0.4–3.1) 1 (0.4–3) 1.7 (0.5–3.1) 0.07
D-dimer, ng/mL 337 (225–565) 317 (217–533) 454 (263–791) 0.02
Lactate dehydrogenase, U/L 195 (173–216) 193 (172–214) 201 (181.2–221.5) 0.10
Ferritin, ng/mL 68 (29–136) 74 (27–125.5) 60 (29–145.2) 0.98
NT-proBNP, pg/mL 73 (37.7–167.2) 74 (38.5–149.0) 80 (34.5–204) 0.39
Chest X-ray
Persistence of any lung injuries, N (%) 52 (26) 22 (15.5) 30 (51.7) 0.001
6MWT: Six minutes walking test; LLN: lower limits of normal; mMRC: Modified Medical Research Council; X-ray: Radiography.
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Table 5. Demographic variables, degree of dyspnoea, health status, capacity for physical exertion, analytical determinations,
and radiological resolution at 12 weeks, according to the presence or absence of alterations in DLNO, or DLNO and DLCO.
Variables DLNO < LLN y DLCO > LLNN = 24
DLNO < LLN y DLCO < LLN
N = 34 p
Demographics
Male sex, N (%), 20 (83.3) 34 (100) 0.01
Age, years 60 (51–69) 68 (61.5–74) 0.02
Dyspnoea According to mMRC
Dyspnoea ≥ 1, N (%) 12 (50) 22 (64.7) 0.20
Dyspnoea ≥ 2, N (%) 3 (12.5) 9 (26.4) 0.19
Dyspnoea 0.5 (0–1) 1 (0–1) 0.06
Health Status According to Nottingham Health Profile
Energy 0 (0–33.3) 0 (0–33.3) 0.88
Pain 6.2 (0–59.3) 12.5 (0–62) 0.51
Physical mobility 31.2 (0–50) 25 (0–50) 0.75
Emotional reactions 11.1 (0–44.4) 11.1 (0–22.6) 0.20
Sleep 30 (0–80) 20 (0–80) 0.99
Social isolation 0 (0–35) 0 (0–20) 0.19
Number of limited areas 3 (2–5) 4 (2–5) 0.84
Respiratory Function Tests
FVC, % of predicted 95 (84–106.2) 89.9 (84–97.5) 0.16
FEV1, % of predicted 94.5 (86.1–105.2) 86.7 (80.7–99) 0.31
DLCO, % of predicted 76 (72.2–80) 55.3 (48.5–65.5) 0.0001
DLNO, % of predicted 69 (62–70) 51.2 (43–63) 0.0001
KCO, % of predicted 96 (84–106.2) 76.3 (68.7–86) 0.0001
KNO, % of predicted 89 (81.2–94) 74.4 (65–83.5) 0.0001
DMCO, % of predicted 56 (50.2–61.7)) 42.5 (33.5–56.2) 0.0001
VC, % of predicted 81 (72.2–88.7) 64 (33.5–56.2) 0.0001
VA, % of predicted 79 (74–87) 72.5 (62.7–84.2) 0.13
Exercise Capacity (6MWT)
6-min walking distance, m 450 (386–509) 434 (347.5–462.7) 0.30
Initial oxygen saturation, % 98 (97–98) 98 (97–98) 0.67
Final oxygen saturation, % 96 (95–97) 95 (92.7–97.2) 0.52
Oxygen saturation drop, % 2 (0.2–3) 2 (1–4.2) 0.30
Borg Scale Dyspnoea Start (1–10) 0 (0–1) 0 (0–0) 0.28
Final Borg scale dyspnoea (1–10) 1.5 (0.2–5.5) 1 (0–4) 0.33
Laboratory Parameters
Lymphocytes × 109/L 2 (1.4–2.5) 1.7 (1.3–2.3) 0.42
C-reactive protein, mg/L 1.7 (0.9–3) 1.8 (0.4–5) 0.94
D-dimer, ng/mL 295 (215.2–523.7) 510 (371.5–954.5) 0.004
Lactate dehydrogenase, U/L 204 (185–222.5) 199 (171.5–218.7) 0.42
Ferritin, ng/mL 55 (21.2–154.2) 83 (31.2–145.2) 0.92
NT-proBNP, pg/mL 76 (22–157.7) 116 (52–375) 0.16
Chest X-ray
Persistence of any lung injuries, N (%) 13 (53.2) 15 (44.1) 0.45
6MWT: Six minutes walking test; DLCO: diffusion capacity of carbon monoxide; DLNO: diffusion capacity of nitric oxide; DMNO: membrane
conductance of nitric oxide; KCO: Rate of uptake of carbon monoxide from alveolar gas; KNO: Rate of uptake of nitric oxide from alveolar
gas; FEV1: forced expiratory volume in first one second; FVC: forced vital capacity; LLN: lower limits of normal; VA: alveolar lung volume;
VC: pulmonary capillary blood volume.
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Table 6 shows the patient demographic and clinical factors prior to admission and the
variables recorded that were related to the severity of the SARS-CoV-2 pneumonic process.
Only three cases of pulmonary embolism were described. In the univariate analysis, both
age and male sex, as well as the presence of various comorbidities and the general condition
of the patient were related to a higher frequency of DLNO alterations. Similarly, variables
related to the severity of the pneumonic process, such as a higher PSI scale score, need for
non-invasive ventilatory support, admission to the ICU, lower oxygen saturation upon
admission, or the peak levels reached for parameters such as total lymphocytes, CRP, LDH,
or D-Dimer, also showed significant differences.
Table 6. Predictive factors for a decrease in DLNO in the univariate analysis.
Variables DLNO > LLNN = 142
DLNO < LLN
N = 58 p
Demographics and Clinical before Admission
Male sex, N (%), 65 (45.8) 54 (93.1) 0.0001
Age, years 61 (46.7–70) 65,5 (56.7–73) 0.03
Body mass index (Kg/m2) 28.7 (25.4–32.3 28.1 (26.6–31.7) 0.59
Previous and current smoker, N (%) 47 (33.1) 37 (63.8) 0.001
History of chronic cardiopathy, N (%) 20 (14.1) 17 (29.3) 0.01
History of diabetes, N (%) 11 (7.7) 12 (20.7) 0.01
History of hypertension, N (%) 47 (33.1) 27 (46.6) 0.07
History of COPD, N (%) 1 (0.7) 5 (8.6) 0.003
History of chronic renal failure, N (%) 3 (2.1) 4 (6.9) 0.11
ECOG score 1 (1–1) 1 (1–2) 0.01
ECOG score ≥ 2, N (%) 29 (20.4) 22 (37.9) 0.01
In Relation to the Pneumonic Process
Bilateral radiographic involvement, N (%) 39 (67.2) 100 (70.4) 0.65
Oxygen saturation at hospital admission 96.5 (94–98) 94.9 (91.5–96) 0.0001
Pneumonia Severity Index 57 (43–67.5) 74 (62–93.5) 0.0001
Pneumonia Severity Index ≥ 3, N (%) 30 (21) 32 (56) 0.0001
Need non-invasive ventilatory support, N (%) 5 (3.5) 7 (12.1) 0.02
ICU admission, N (%) 14 (9.9) 17 (29.3) 0.001
Lowest level of lymphocites (109/L) 0.82 (0.59–1.18) 0.60 (0.42–0.81) 0.0001
Maximum level of C-reactive protein (mg/L) 62.4 (23.6–138.5) 148.6 (88.6–217.7) 0.0001
Maximum level of lactate dehydrogenase (U/L) 277 (219.5–343.2) 367.5 (265.2–464.2) 0.005
Maximum level of D-dimer (ng/mL) * 690.1 (423–2221.7) 1881.5 (980–4018) 0.001
Length of stay (days) 8.8 (3–11) 10.5 (6–26) 0.0001
* Available in 94 patients only; COPD: Chronic obstructive pulmonary disease; DLCO: diffusion capacity of carbon monoxide; DLNO:
diffusion capacity of nitric oxide; DMNO: membrane conductance of nitric oxide; ECOG: Eastern Cooperative Oncology Group; KCO:
Rate of uptake of carbon monoxide from alveolar gas; KNO: Rate of uptake of nitric oxide from alveolar gas; FEV1: forced expiratory
volume in first one second; FVC: forced vital capacity; ICU: Intensive care unit; LLN: lower limits of normal; VA: alveolar lung volume; VC:
pulmonary capillary blood volume.
In the multivariate analysis, male sex (OR = 6; 95CI% = 1.7–20; p = 004), age
(OR = 0.93; 95CI% = 0.89–0.98; p = 0.009), days of admission (OR = 1.03; 95CI% = 1.01–1.06;
p = 0.009), and the PSI score (OR = 1.07; 95CI% = 1.03–1.1; p = 0.0001) were independently
related to the presence of a reduced DLNO 12 weeks after hospital discharge.
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4. Discussion
This study provides novel information because it is one of the first to include an
analysis of DLNO among the RFTs performed three months after discharge of patients
hospitalised for SARS-CoV-2 pneumonia. One of the main conclusions of this work is that
the DLNO lung function test results are most frequently altered in these patients, with this
alteration present in almost double the number of patients with decreased DLCO (currently
the most studied diffusion test in this context). Altered DLNO was related to the degree
of dyspnoea three months after discharge; it was also associated with the persistence of
lesions on patient radiographs and affected these patients’ health status and capacity for
physical exertion. Age and sex, as well as the severity of the process, helped to predict this
functional alteration.
Although this technique is not routinely used in clinical practice, the evidence available
for various diffuse cardiopulmonary pathologies indicates that evaluating pulmonary
diffusion using the combination of DLNO and DLCO is more sensitive than evaluating
DLCO alone [17–20]. Some 40% of the patients with a decreased DLNO presented a DLCO
within normal limits, with a higher proportion of women and younger patients in this
group. The impact of COVID-19 pneumonia on the health and limitations in terms of
physical exertion in these patients was higher than those without diffusion alterations.
While both the DLNO and DLCO techniques depend on the same components (mem-
brane conductance and the vascular component), DLCO is more sensitive to microvas-
cular alterations while DLNO is more influenced by the membrane component of diffu-
sion [17,18,21]. The fact that one of the possible pulmonary effects of COVID-19 is small
vessel microthrombosis [28] could perhaps explain the elevated D-Dimer levels we found
in patients with combined alterations in both DLCO and DLNO, as well as the different
intensity of Vc involvement compared to patients in which only DLNO was altered. This
finding could perhaps also explain the persistent symptoms present in many of these
patients in whom no alterations were observed in conventional pulmonary function tests,
including DLCO. However, it is important to consider that the association between the
persistence of symptoms, their severity, and alterations in pulmonary function tests is
variable in work published to date [29].
Notwithstanding, this current work reveals the limited concordance between many
other RFTs, which may reflect the complexity of the structural involvement in patients
who have suffered severe COVID-19 pneumonia. These patients may suffer persistent
lesions at the level of the parenchyma, distal airways, and small pulmonary vessels (as en-
dothelitis or microthrombosis), as well as haemodynamic alterations that can compromise
the ventilation/perfusion balance, all for varying amounts of time [12–17]. In addition,
patients’ own underlying diseases, the frequent need for high oxygen concentrations for
several days (with the consequent risk of hyperoxia), interrelation between different func-
tional parameters (such as the influence of the VA), and variability in performance of each
evaluation technique, may also influence the heterogeneity seen in the work published so
far [12–17,30].
In our opinion, the first priority for the RFTs used to assess the impact of COVID-
19 infection must correlate well with the symptoms and limitations presented by the
patient and thus, be able to explain them and thereby avoid the unnecessary search for
other possible aetiologies (such as cardiac, muscular, or psychological alterations). Most
importantly, these tests must be able to reliably predict functional alterations based on
variables that are easy to register (either from the patient or according to the severity
of the process) because this will allow physicians to prioritise interventions and initiate
preventive and rehabilitative strategies early on [31].
Based on the results of our study, the DLNO test best meets these previously mentioned
criteria. Measurement of the different components of diffusion can allow earlier and more
precise identification of microvascular alterations. Barisione and Brusasco have recently
published that these alterations evolve differently in the longer term [17]. Moreover, there
are some technical advantages to DLNO over conventional DLCO, such as the fact that it
J. Clin. Med. 2021, 10, 2119 11 of 14
is independent from haemoglobin and lung volumes, which can be important in patients
with comorbidities and the sequelae of severe respiratory disease.
The scarcity of previous studies evaluating DLNO makes it difficult to contextualise
this work within the existing academic literature. Furthermore, the few series that have
been published regarding functional alterations detected three-to-four months after a
COVID-19 pneumonic episode mainly examined the DLCO [1–10]. As shown in the table
summarising these studies (Table 7), and despite the fact that there is little variation in
the percentage over the reference value of DLCO, when the alteration was defined by a
decrease under 80% in the theoretical percentage (51–57%), except for series that include
only post-ICU patients [10]; however, when this was measured as a decrease below the
LLN, DLCO alteration ranged from 17% in our work to 24% as reported by Lerum et al. [1],
and 34% in another study nine weeks after discharge [32].
Table 7. Comparison of the principal variables of the main published series that had evaluated pulmonary function tests



























Country Norway Canada China Spain Spain Italy Italy Switzerland
Time from hospital
discharge, months 3 3 3 3 3 4 4 4
N 103 60 88 172 62 222 219 47 Mild 66 Severe
Male sex, % 52 68 42 57 74.2 57.2 59.7 52.9 60
Age, years 59 67 59 56.1 60 58 61 57.4 60.3
BMI 25.8 25 23.8 - 28.2 26.2 - 25.5 29.8
Current or previous
smoking, % 36 38 - 27.3 56.7 37.9 41.1 37 56
ICU admission, % 15 - - 43 100 15.3 11.8 -
Length of stay (days) 6 10 - - - -
Diabetes, % 8 22 9 14.5 14.5 9.5 15.1 0 35
COPD or asthma % - 13 - 11.6 9.6 9.1 5.8 22 21
Hypertension, % 35 35 28 33.1 37.1 39.6 41.2 8 55
Cardiopathy, % - 10 9 13.9 9.4 15.3 16.3 9 10
Dyspnoea mMRC > 0 54 20 48.8 46.7 48.2 5.5 - -
Dyspnoea mMRC > 1 - - - - 20.7 - - -
Chest CT Yes Yes - No Yes No No Yes
FVC, % 94 94 89.7 90 81.5 105 98.5 95.6 86.6
FEV1, % 92 93 92.9 94 88.9 106 101 94 89.4
DLCO, % 83 77 82-6 - - - 79 95.3 72.2
DLCO < LLN, % 24 - - - - - - - -
DLCO < 80%, % - 52 54 57 82 - 51.6 - -
DLCO/VA, % 95 - 86.1 - - 101 - - -
DLCO/VA < 80% 38 - .
6-min walking
distance, m 580 504 - - 400 500 - 576 456
BMI: body mass index; COPD: chronic obstructive pulmonary diseases; CT: computerized tomography; DLCO: diffusion capacity of carbon
monoxide; FEV1: forced expiratory volume in first one second; FVC: forced vital capacity; LLN: lower limits of normal; VA: alveolar
lung volume.
In other studies, the relationship between predictor variables and lung involvement
was enhanced by different linear correlation analyses without defining specific cut-off
points for the definition of DLCO alteration [6,8].
These different definitions can influence the capacity of DLCO to predict the func-
tional sequelae of the different variables analysed. However, as we observed in this
present work, and consistent with the results from the only published study that evalu-
ated patients six months after infection with SARS-CoV-2 [33], these variables are usually
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associated with parameters related to the severity of the pneumonic episode (e.g., prog-
nostic scales, value of analytical determinations indicative of greater inflammation) and
intensity of the supportive therapy required during patient admission [1–8]. One study
found that cardiorespiratory comorbidities and female sex predicted DLCO < 80%, but not
DLCO < 60% [7]. However, other studies found that men tended to be affected more
often [2], which agrees with our series in which the male sex was a powerful predictive
factor of decreased DLCO. Although this factor requires more research, male sex was a
predictor for the long-term development of fibrosis in other coronavirus infections such as
SARS [34].
The main limitation of this study was that it was carried out in a single centre and the
number of patients who required admission to the intensive care unit was lower than in
other studies It should be taken into account when interpreting the results. However, the
general characteristics of the patients we included, as well as the values of the variables
analysed in the series published so far, are relatively superimposable, meaning that it is
possible to extrapolate our results to other centres and countries.
In addition, we did not systematically include data from more sophisticated imaging
techniques such as chest computed tomography or echocardiography that could have
helped better define the degree of pulmonary involvement or the coexistence of other
cardiovascular diseases. Also, as in the other studies published so far, the value of lung
function tests prior to COVID-19 was not available and we have not excluded patients with
a history of smoking or with cardiovascular comorbidity, which could influence the results.
We consider the strengths of our work to be the fact that we consecutively recruit
patients in a tertiary hospital which provides health coverage to 95% of the reference
population, an acceptable casuistry compared to other published work. We have collected
a remarkable number of variables that we analysed at three months and it is one of the
few published studies that includes the determination of DLNO among lung function
tests. We used definitions based on recommendations by scientific societies, and all tests
were performed by the same professionals with more than 10 years of experience (thereby
helping to reduce variability in the results).
5. Conclusions
Combined determination of DLCO and DLNO was the most sensitive test to evaluate
the medium-term sequelae of severe COVID-19 pneumonias in our patient cohort. Altered
DLCO–DLNO was related to the severity of patient symptoms and their health status and
could be predicted by sociodemographic factors and the severity of the pneumonic process.
These findings may be useful for evaluating patients with persistent symptoms who do
not present alterations in commonly used RFTs. Similar studies will be required to increase
the evidence in this field and to improve our knowledge of the possible sequelae of lung
involvement in COVID-19 and its evolution over time [17].
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